ArticleBMC cancer2025

Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.

Jianlin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.